Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants
Sponsor: Latigo Biotherapeutics
Summary
This is a sequential, randomized, double-blind, placebo-controlled Phase 1 single (SAD) and multiple (MAD) ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally or intravenously administered LTG-001 in healthy male and female participants
Official title: A Sequential, Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally of Intravenously to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Male and Female Participants 18 to 55 Years of Age
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
204
Start Date
2023-10-17
Completion Date
2026-04-28
Last Updated
2026-01-23
Healthy Volunteers
Yes
Conditions
Interventions
LTG-001
Oral doses
Placebo
Oral doses
Locations (1)
Clinical Research Unit
Christchurch, New Zealand